1. Autologous Bone Marrow Stem Cell Therapy in Patients With ST-Elevation Myocardial Infarction: A Systematic Review and Meta-analysis 
Maya M. Jeyaraman, MD, PhD, Rasheda Rabbani, PhD, Leslie Copstein, MD, MPH, Wasan Sulaiman, MD, MPH, Farnaz Farshidfar, MD, MSc, Hessam H. Kashani, MD, MSc, Sheikh M.Z. Qadar, MSc, Qingdong Guan, PhD, Becky Skidmore, BA, MLIS, Elissavet Kardami, PhD, John Ducas, MD, Samer Mansour, MD, Ryan Zarychanski, MD, MSc, Ahmed M. Abou-Setta, MD, PhD 
Canadian Journal of Cardiology 
Volume 33, Issue 12, Pages (December 2017)
DOI: /j.cjca
Copyright © 2017 Canadian Cardiovascular Society Terms and Conditions

2. Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) study flow diagram depicting study selection process.
Canadian Journal of Cardiology  , DOI: ( /j.cjca )
Copyright © 2017 Canadian Cardiovascular Society Terms and Conditions

3. Figure 2
Bone marrow stem cell (BMSC) therapy and risk of all-cause mortality.
Forest plot depicts the risk of all-cause mortality after BMSC therapy in ST-elevation myocardial infarction patients after primary percutaneous coronary intervention compared with the control group. The lines represent 95% confidence interval (CI) and the size of the boxes is proportional to the weight of each study in the analysis.
Canadian Journal of Cardiology  , DOI: ( /j.cjca )
Copyright © 2017 Canadian Cardiovascular Society Terms and Conditions

4. Figure 3
Cumulative effect size of bone marrow stem cell (BMSC) therapy in ST-elevation myocardial infarction patients. The trial sequential analysis plot depicts the points indicating cumulative meta-analysis (Z-curve), the conventional significance boundaries (horizontal black lines), the trial sequential monitoring boundaries (horizontal red lines), and the futility boundaries (funnel shaped red lines in the centre).
Canadian Journal of Cardiology  , DOI: ( /j.cjca )
Copyright © 2017 Canadian Cardiovascular Society Terms and Conditions